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Abstract 
 Psychiatric research has been hampered by an explanatory gap between psychiatric 
symptoms and their neural underpinnings, which has resulted in poor treatment outcomes. This 
situation has prompted us to shift from symptom-based diagnosis to data-driven diagnosis, aiming 
to redefine psychiatric disorders as disorders of neural circuitry. Promising candidates for data-
driven diagnosis include resting-state functional connectivity MRI (rs-fcMRI)-based biomarkers. 
Although biomarkers have been developed with the aim of diagnosing patients and predicting the 
efficacy of therapy, the focus has shifted to the identification of biomarkers that represent 
therapeutic targets, which would allow for more personalized treatment approaches. This type of 
biomarker (i.e., “theranostic biomarker”) is expected to elucidate the disease mechanism of 
psychiatric conditions and to offer an individualized neural circuit-based therapeutic target based 
on the neural cause of a condition. To this end, researchers have developed rs-fcMRI-based 
biomarkers and investigated a causal relationship between potential biomarkers and disease-
specific behavior using functional MRI (fMRI)-based neurofeedback on functional connectivity. 
In this review, we introduce recent approach for creating a theranostic biomarker, which consists 
mainly of two parts: (i) developing an rs-fcMRI-based biomarker that can predict diagnosis and/or 
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symptoms with high accuracy, and (ii) the introduction of a proof-of-concept study investigating 
the relationship between normalizing the biomarker and symptom changes using fMRI-based 
neurofeedback. In parallel with the introduction of recent studies, we review rs-fcMRI-based 
biomarker and fMRI-based neurofeedback, focusing on the technological improvements and 
limitations associated with clinical use.  
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Introduction 
Although great advancements in psychiatric research have been made in recent years, 
an explanatory gap between phenomenological entities and neurobiological underpinnings 
remains (Montague et al., 2012). This gap has prevented precise diagnosis and dramatic 
improvements in treatment outcomes in the field of clinical psychiatry (Insel and Cuthbert, 2015). 
Our lack of understanding of the disease mechanisms is reflected by the fact that the two world-
wide standard psychiatric diagnosis systems—the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) (American Psychiatric Association, 2013) and International Classification of 
Diseases (ICD) (World Health Organization, 1990)— adopt symptom-based approaches, in 
which underlying biological substrates are not taken into consideration (Insel and Cuthbert, 2009), 
except in the case of dementia. Consequently, these symptom-based diagnostic systems may 
artificially draw distinctions among conditions that actually share common biological etiologies, 
and therefore, may fail to provide effective biology-based treatments directed toward specific 
pathogenic processes associated with these conditions (Owen, 2014). Therefore, the recent 
initiative of research domain criteria (RDoC) has proposed an important paradigm shift from the 
conventional symptom-based categories to data-driven dimensional approaches based on 
 6 
observable behaviors and neurobiological measures (Insel and Cuthbert, 2009), with the aim of 
eliminating the gap between disease-related behaviors and neurobiological substrates. In this 
review, we first explain that brain functional measures provided by fMRI, particularly the resting-
state functional connectivity (rs-fc) MRI, play crucial roles for the development of “biomarkers” 
that provide dimensions along which various psychiatric disorders could be defined. Then, we 
illustrate the potential and power of the fMRI- and biomarker-based neurofeedback methods in 
the treatments of disease-related behaviors. By illustrating the development of rs-fcMRI-based 
biomarkers and fMRI-based neurofeedback, we claim that these two lines of new research 
converge in filling the abovementioned gap. 
 
Towards development of theranostic biomarker for psychiatric disorder 
Recent psychiatric neuroimaging research has begun to bridge the explanatory gap by 
redefining psychiatric disorders as disorders of neural circuitry (Insel and Cuthbert, 2015). Indeed, 
rs-fcMRI represents a promising platform for identifying affected neural circuitry. Traditionally, 
alterations in neural circuitry have been studied by examining brain activation and/or functional 
connectivity (FC) during specific task conditions using a limited number of participants. However, 
more recent whole-brain rs-fcMRI studies have applied state-of-the-art machine learning 
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algorithms to “big data” in order to identify brain features that predict the diagnostic status and/or 
severity of psychiatric disease (Clementz et al., 2016; Yahata et al., 2016 and 2017; Arbabshirani 
et al., 2017). Since brain features are identified in a data-driven manner, this approach is free of 
potential biases that may derive from explicit hypotheses regarding affected brain regions, FCs, 
or functions. Furthermore, relative to task-based fMRI, rs-fcMRI is more suited to the clinical 
investigation of patients and young children who have difficulty in performing tasks (Poldrack 
and Farah, 2015). In addition, previous studies have shown that resting brain signals generate 
highly structured spatiotemporal patterns that correspond well to those observed when performing 
tasks (Smith et al., 2009; Laird et al., 2011). These signals predict brain activation evoked by 
several kinds of tasks at the level of individual participant (Tavor et al., 2016). These studies 
indicate that rs-fcMRI data may include abundant information regarding individual characteristics 
and that this data can therefore be used as a substitute for task-based fMRI data. Together with 
the relative simplicity and low variability in data acquisition setups, rs-fcMRI serves as the 
platform by which large amounts of clinical data can be analyzed to develop appropriate machine-
learning algorithms.   
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Many studies along this line of psychiatric research share the goal of identifying 
biological measures of altered neural circuitry that represent “biomarkers” for psychiatric 
disorders (Perlis, 2011; Abi-Dargham and Horga, 2016). Indeed, to date, a number of structural 
and functional MRI studies have claimed to have identified such “biomarkers” for various 
psychiatric disorders (Fan et al., 2008; Sun et al., 2009; Kim et al., 2010; Sui et al., 2015; Ivleva 
et al., 2016; Kambeitz et al., 2016; Drysdale et al., 2017; Li et al., 2017). However, the 
significance of these identified biomarkers varies greatly depending on study aims and designs. 
Here, we propose that so-called “biomarkers” should be categorized into the following four types: 
(i) biomarker “candidates” that correlate with diagnosis in a sample pool, (ii) those that generalize 
over the studied samples and therefore predict diagnosis of a disease of interest in a general 
population, (iii) those that predict the effect of a therapy (i.e., surrogate endpoint), and (iv) those 
that correspond to the disease mechanism and may therefore be regarded as therapeutic targets. 
Biomarker types (i) and (ii) are similar in that the measure simply represents a correlation with 
the disease status, though they are critically different regarding whether the scope of the 
biomarker is limited to the sample dataset (i) or has the capacity to generalize over the disease of 
interest in general, beyond the sample (ii). In this sense, only biomarker types (ii)-(iv) qualify as 
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true “biomarkers” (Abi-Dargham and Horga, 2016). While biomarker types (ii) and (iii) can be 
used as an auxiliary test in clinical practice and are expected to provide important information 
regarding the diagnosis and treatment strategy, the clinical importance of these two types of 
biomarkers does not necessarily indicate that these measures account for the disease mechanism. 
For instance, low-density lipoprotein (LDL) cholesterol has been used as a surrogate marker for 
a clinically meaningful endpoint for the heart disease. However, lowering LDL cholesterol does 
not necessarily lead to the prevention of heart disease at the individual level because the density 
of LDL cholesterol may not be associated with the underlying cause of heart disease (Albert, 
2011). In contrast, when the biomarker corresponds to elements of the disease mechanism as in 
type (iv), its significance is two-fold: as a measure of diagnostic status and/or the severity of 
symptoms, and as a therapeutic target. Therefore, we refer to this type of biomarker as a 
“theranostic biomarker”. The development of such theranostic biomarkers will result in 
breakthroughs not only in basic biological research but also in clinical psychiatry practice, 
providing patients with individually tailored therapeutic targets and allowing for the elimination 
of unnecessary treatments and adverse effects (Ahn, 2016). 
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Hereafter, we introduce several recent studies that have suggested that some rs-fcMRI-
based biomarkers satisfy prerequisites for type (ii), (iii), and even (iv) biomarkers for major 
psychiatric disorders. That is, these biomarkers may explain elements of disease mechanisms and 
identify a therapeutic target for a range of neuromodulation interventions, including 
neuropharmacology, repetitive transcranial magnetic stimulation (rTMS), and neurofeedback. In 
order to strictly verify that the rs-fcMRI-based biomarker represents the disease mechanism, the 
following three levels of evidence are necessary: (A) The rs-fcMRI-based biomarker predicts 
diagnostic status and/or the severity of symptoms with high accuracy for the general population 
of a disease of interest; (B) normalization of the biomarker via neuromodulation interventions 
leads to the alleviation of symptoms; and (C) alterations of neural circuits that are represented by 
the biomarker are caused by a whole range of known risk factors for the disease of interest, 
including genes, molecules, cells, circuits, cognition, behavior, and the physical and social 
environments. However, it is very difficult to provide the third level of evidence due to the limited 
datasets obtained in human studies. Consequently, we discuss the first two levels of evidence to 
examine whether rs-fcMRI-based biomarkers are capable of acting as theranostic biomarkers for 
psychiatric disorders. Concretely, we first introduce the development of the rs-fcMRI-based 
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biomarkers for autism spectrum disorder (ASD), major depressive disorder (MDD), 
schizophrenia (SCZ), and obsessive compulsive disorder (OCD)—which utilized state-of-the-art 
machine learning algorithms that achieved high classification accuracy and generalized well for 
independent validation cohorts. Secondly, we introduce the preliminary results of recent proof-
of-concept studies that have examined whether the normalization of rs-fcMRI-based biomarker 
can be achieved via fMRI-based neurofeedback on FC, and whether such normalization leads to 
the improvement of symptoms in depression. In addition, we also refer to technical difficulties in 
the development of rs-fcMRI-based biomarkers and fMRI-based neurofeedback and discuss 
recent advances in overcoming these challenges.  
 
Rs-fcMRI-based biomarker for psychiatric disorder 
The importance of rs-fcMRI-based biomarkers for psychiatric disorders 
 The brain generates highly structured spatiotemporal patterns even in the absence of 
explicit task execution (i.e., under resting-state conditions) (Smith et al., 2009; Laird et al., 2011). 
This finding suggests that rich information may be decoded by applying machine learning 
algorithms to rs-fcMRI data in the individual brain. Indeed, a series of studies have successfully 
used such algorithms to predict various characteristics in healthy individuals, including age 
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(Dosenbach et al., 2010), intelligence (Smith et al., 2015), working memory (Yamashita et al., 
2015), and sustained attention (Rosenberg et al., 2016). Based on these successful applications, a 
growing number of studies have sought to develop rs-fcMRI-based biomarkers for various 
psychiatric disorders (Arbabshirani et al., 2017), such as ASD (Anderson et al., 2011), MDD 
(Drysdale et al., 2017), SCZ (Kaufmann et al., 2015), and ADHD (Deshpande et al., 2015).  
 
The generalization ability of rs-fcMRI-based biomarkers 
 A number of rs-fcMRI-based biomarker studies have claimed high accuracy in 
discrimination between individuals with a disease of interest and healthy controls (HC) for most 
major psychiatric disorders. However, to date, no such biomarkers have been identified for use in 
routine clinical practice. Aside from issues related to economic and practical feasibility in clinical 
settings, one major issue with previously developed biomarkers is that accuracy in discrimination 
of the biomarker is validated only for a single sample cohort that is shared with the training of the 
biomarker. Therefore, the generalizability of the biomarker is usually untested beyond the sample 
dataset, and highly accurate discrimination is likely to fail when that biomarker is applied to an 
independent cohort. More specifically, if the developed biomarker is fitted to noise structures that 
are specific to the training dataset (e.g., demographic distributions and measurement conditions 
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such as the type of MRI scan protocol), the prediction is inflated for the training data but 
catastrophic to the independent validation dataset, which does not contain the same noise structure 
(Whelan and Garavan, 2014; Huys et al., 2016; Yahata et al., 2017). 
In order to develop clinically meaningful rs-fcMRI-based biomarkers, it is necessary 
to prove the generalizability of the biomarker using independent datasets as validation cohorts. 
For this step to be successful, the development of optimal machine-learning algorithms that 
alleviate over-fitting to the noise structures of the training data is critical. Such over-fitting often 
occurs when a large number of parameters are included relative to the number of participants, and 
when the model does not sufficiently remove the effect of nuisance variables that are included in 
training dataset (Whelan and Garavan, 2014; Yahata et al., 2017). Therefore, for the model to be 
reliable, the number of parameters in the model should be reduced based on the number of 
participants, and the brain features that reflect disease-related factors (e.g. diagnostic status and 
symptom severity) should be extracted after removing the data-specific noise structure. In the 
following section, we review the development of rs-fcMRI-based biomarkers that satisfy the 
aforementioned conditions for ASD (Yahata et al., 2016), MDD (Ichikawa et al., 2017), SCZ 
(Yoshihara et al., 2017), and OCD (Takagi et al., 2017). In illustrating these cases, we show that 
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the overfitting problem was successfully alleviated by the development of novel machine-learning 
algorithms, which resulted in the identification of a small number of altered functional 
connections (FCs) capable of discriminating between individuals with a specific medical 
condition of interest and healthy or typically developed controls (HC or TD). The resultant 
biomarker has achieved high accuracy for a discovery cohort (i.e., training data), together with 
good generalizability for independent validation cohorts (i.e., test data).   
 
The rs-fcMRI-based biomarker for ASD  
 Although it is generally believed that abnormal FCs may underlie ASD (Menon, 2011), 
whether such abnormalities involve under-connectivity, over-connectivity, or distance-dependent 
alterations (Just et al., 2012; Supekar et al, 2013; Long et al., 2016) remains unknown. Several 
research groups have attempted to solve this problem by developing rs-fcMRI-based biomarkers. 
However, none of these biomarkers has been validated in an independent cohort (Anderson et al., 
2011). One study that attempted to validate the generalizability of the biomarker observed poor 
performance below chance in an independent cohort (Yoshihara et al. 2011). Among these 
unsatisfactory attempts to develop an rs-fcMRI biomarker for ASD, Yahata et al. (2016), aimed 
to achieve a desired level of generalizability by controlling the two causes of over-fitting: the 
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number of parameters in the model and the interference of nuisance variables. Specifically, they 
developed a unique combination of machine-learning algorithms of L1 regularized sparse 
canonical correlation analysis (L1-SCCA) followed by sparse logistic regression (SLR; 
Yamashita et al., 2008). Briefly, in this algorithm, L1-SCCA was applied to extract FC features 
associated with diagnostic labels (e.g., ASD or TD), while removing FC features associated with 
nuisance variables (e.g., age, sex, medication, scan protocol). Then, sparse estimation performed 
by L1-SCCA and SLR reduced the number of explanatory variables (i.e., FCs) in the biomarker. 
Therefore, the combination of L1-SCCA and SLR is highly suited for controlling the 
aforementioned two causes of over-fitting inherent to machine-learning studies using multicenter 
rs-fcMRI data.  
Yahata et al. (2016) applied this novel machine learning algorithm to rs-fcMRI data 
from 74 high-functioning adults with ASD and 107 TD adults obtained from three different sites 
in Japan. FC data in each individual were analyzed as a correlation matrix representing the 
Pearson correlation values for 9,730 pairs of time-series data extracted from 140 regions in the 
sulci-based anatomical atlas (extended Brainvisa Sulci Atlas; Perrot et al., 2011). Using the 
correlation matrices of 181 individuals as inputs, the machine learning algorithm of L1-SCCA 
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and SLR generated a classifier consisted of only 16 FCs (0.2% of all FCs) that distinguished 
between ASDs and TD with a high accuracy of 85% and an area under the curve (AUC) of 0.93 
(Figure 1a).  
Because the biomarker for ASD was developed using Japanese datasets only, it must 
be validated using independent cohort datasets, which, in this study, were collected in countries 
with different cultural and ethnic backgrounds than those in Japan. Therefore, the US ABIDE 
dataset was selected as an independent cohort (Di Martino et al., 2014), which consisted of 44 
high-functioning adults with ASD and 44 demographically matched TD controls. Indeed, the 
biomarker developed in Japan generalized well and exhibited a high classification accuracy of 
75% (AUC=0.76) (Figure 1b). To our knowledge, this is the first study to demonstrate high 
generalizability for an independent cohort across cultures and ethnicities. The generalizability of 
the biomarker was further confirmed in a second independent cohort collected in Japan (Accuracy 
= 70%, AUC = 0.77). Lastly, the selected FCs used in the developed biomarker predicted with 
high accuracy not only diagnostic status but also the severity of communication problems, based 
on communication domain scores of the Autism Diagnostic Observation Schedule (ADOS) (Lord 
et al., 2000) (r = 0.44, p < 0.001). These results indicate that, with the proper use of machine-
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learning algorithms for controlling over-fitting, we are able to develop a reliable biomarker from 
the rs-fcMRI data that predicts ASD with high accuracy.  
Further, we applied this ASD biomarker to other psychiatric disorders (SCZ, ADHD, 
and MDD) to investigate whether the selected FCs could discriminate patients with these 
psychiatric disorders from healthy controls. That is, we aimed to determine whether the 
biomarker is specific to ASD diagnosis. Our results indicated that this biomarker could not 
significantly differentiate individuals with ADHD or MDD from their respective controls 
(ADHD: AUC = 0.57, p =0.65, MDD: AUC = 0.48, p = 0.83), although moderate differentiation 
of those with SCZ was observed (AUC = 0.65, p = 0.012) (Figure 1c). This modest 
generalizability of the constructed ASD biomarker only to SCZ indicates that the weighted 
summation of the extracted FCs for the biomarker may reflect the extent of “ASD-ness”, or 
more precisely liability of ASD, as individuals throughout any population—including those 
with other psychiatric conditions—may possess ASD-like traits. This speculation is biologically 
plausible considering the evidence that ASD is closer to SCZ than ADHD and MDD in terms of 
genetic, behavioral, and neuroimaging findings (King and Lord, 2011; Cross-Disorder Group of 
the Psychiatric Genomics Consortium, 2013).  
 18 
 
Figure 1 
 
 
The generalizable rs-fcMRI-based biomarkers for depression, schizophrenia, and obsessive 
compulsive disorder 
 The classifier construction algorithm developed in Yahata et al. (2016) was applied to 
patients with melancholic depression, SCZ, and OCD. Ichikawa et al. (2017) restricted the 
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training samples to individuals with melancholic depression (N = 66) and demographically 
matched healthy controls with Beck Depression Inventory-II (BDI-II) scores ≤ 10 (Beck et al., 
1996) (N = 66) to avoid issues in the heterogeneity of depression (CONVERGE consortium, 
2015). The resulting classifier identified 12 diagnosis-specific FCs (out of 9,316 connections) and 
achieved high discriminability (AUC = 0.77, Accuracy = 70%) in the training dataset and high 
generalizability (AUC = 0.62, Accuracy = 65%) to the independent validation cohort (i.e., test 
data), which included individuals with melancholic depression (N = 11) and healthy controls (N 
= 40). (These healthy controls were matched based on BDI score to those in the training dataset.)  
A biomarker for SCZ (AUC = 0.83, Accuracy = 76%) using a Japanese training dataset 
consisting of patients in the chronic stage (duration of illness = 12.8 ± 7.8 years), scanned at two 
imaging sites in Japan, was also developed (Yujiro Yoshihara, personal communication, March 
30, 2017). The SCZ biomarker also worked well for two independent validation cohorts of 
patients in the chronic stage (USA site 1: duration of illness = 14.2 ± 11.5 years, AUC = 0.75, 
Accuracy = 70%, EU site: duration of illness = 5.9 ± 5.8 years, AUC = 0.66, Accuracy = 61%), 
but not for a test dataset of patients experiencing their first episode (USA site 2: duration of illness 
= 16.8 ± 9.6 months, AUC = 0.42, Accuracy = 45%). These findings suggest that each stage of 
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SCZ is associated with specific pathological processes manifested as differentially altered FCs, 
in accordance with the findings of previous studies (Anticevic et al., 2015; Li et al., 2016).   
For the discrimination of OCD, Takagi et al. (2017) adopted the methodology for 
developing rs-fcMRI based biomarkers described by Yahata et al (2016) in conjunction with 
principal component analysis for feature selection of FCs, partly because a small training data set 
from a single imaging site was available. All principal components were analyzed using the 
aforementioned algorithm (L1-SCCA and SLR). The biomarker for the training dataset (NOCD = 52, 
NHC = 56) exhibited high accuracy (AUC: 0.81, Accuracy: 73%), while that for the test dataset (NOCD 
= 18, NHC = 10) exhibited high generalizability (AUC: 0.70). 
 
Neurofeedback 
fMRI-based neurofeedback 
 Neurofeedback is an auxiliary technique for self-regulating the neural activity that 
underpins specific behaviors or symptoms by providing participants with real-time feedback 
that represents the current activity state of the neural activity of interest (Sitaram et al., 2016; 
Thibault et al., 2016). In contrast to other neuromodulation methods that rely on externally 
applied factors (e.g. electromagnetic field and pharmacological agents), neurofeedback is a 
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method of internally (either volitionally or conditionally) regulating neural activity. As such, 
this method provides a means to aid participants to learn to induce brain activity toward a 
desired pattern of neural activity relying only on participants’ own endogenous factors. Among 
several neuroimaging modalities including electroencephalography (EEG) and functional near-
infrared spectroscopy (fNIRS), fMRI-based neurofeedback has attracted considerable attention 
for its potential as a novel method of therapeutic treatment in clinical neuroscience (Fovet et al., 
2015; Morimoto and Kawato, 2015). To date, several studies have applied fMRI-based 
neurofeedback methods to psychiatric patients by training them to up-regulate or down-regulate 
the level of activation in single or multiple regions-of-interest (ROI) (Sitaram et al., 2016). 
Although this method has proven effective for some psychiatric conditions (Linden et al., 2012; 
Scheinost et al., 2013; Sitaram et al., 2014; Zilverstand et al., 2017), recent advances in fMRI 
data acquisition and analysis have enabled us to evaluate fMRI signals with greater spatial and 
temporal precision in real-time. This technological advance has yielded two novel lines of 
fMRI-based neurofeedback: decoded neurofeedback (DecNef) and functional-connectivity-
based neurofeedback (FCNef). DecNef is a novel method of controlling distributed activity 
patterns of multiple voxels within a circumscribed ROI (Shibata et al., 2011) (Figure 2), thereby 
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greatly increasing spatial precision over the previous method of regulation of localized activity 
in coarsely defined ROIs. In contrast, FCNef allows for the modulation of spatiotemporal 
activation patterns across multiple ROIs (Koush et al., 2013; Koush et al., 2015) as well as 
intrinsic functional networks (Megumi et al., 2015) (Figure 3). In the following sections, we 
review recent successful applications of DecNef and FCNef, which, in our view, have potential 
as novel interventions for the treatment of psychiatric disorders via powerful regulation of 
neural activity (Yanagisawa et al., 2016; Sakai, 2016).  
 
Figure 2 
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Figure 3 
 
 
Decoded neurofeedback (DecNef) 
DecNef is a novel neurofeedback method in which participants learn to induce specific 
activation patterns of multiple voxels in a given brain region. This neurofeedback method is based 
on recently developed fMRI decoding techniques (Kamitani and Tong, 2005), which allow 
researchers to infer the mental experiences and states of participants via analysis of multi-voxel 
patterns of activation. DecNef is thus based on the assumption that, by determining a particular 
multi-voxel pattern as a target pattern that corresponds to a specific mental experience or state, 
experimenters can calculate the similarity between the target and the current multi-voxel pattern 
online and return it to participants as a feedback score. DecNef studies are usually composed of 
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three types of experiments: (i) pre- and post-behavioral tests, (ii) fMRI decoder construction, and 
(iii) DecNef training (Shibata et al., 2011, 2016; Amano et al., 2016; Koizmi et al., 2016; Cortese 
et al., 2016 and 2017). The pre- and post-behavioral tests examine whether the DecNef method 
can alter the target behavior in the desired direction (e.g., whether DecNef can enhance visual 
perceptual learning). In the fMRI decoder construction stage, multi-voxel patterns of activation 
corresponding to the target mental experience or state (e.g., visual perception of gratings with 
orientation of 45 degrees) are identified via a stimulus-driven and task-based fMRI experiment. 
In the DecNef training stage, participants learn to induce the decoded multi-voxel pattern of 
activation matched with the target mental experience or state through neurofeedback. In the 
following paragraph, we mainly review three DecNef studies, in which researchers aimed to alter 
three types of behavior: 1) visual perceptual learning, 2) meta-cognition, and 3) fear response. 
Shibata et al. (2011) demonstrated that the DecNef method may aid participants in 
inducing target spatiotemporal patterns of activation in the primary visual cortex corresponding 
to a specific orientation of Gabor patches, without the presentation of a matched stimulus. 
Furthermore, the authors observed that this method resulted in visual perceptual learning specific 
to the target orientation. These results and characteristics indicate that DecNef has the potential 
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to induce sufficient neuro-plasticity for perceptual learning in the adult early visual cortex with 
high selectivity.  
Based on the findings of this seminal study, DecNef has now been extended to the 
associative learning (Amano et al., 2016), face preference (Shibata et al., 2016), meta-cognition 
(Cortese et al., 2016) and fear extinction paradigms (Koizumi et al., 2016). In the following 
paragraphs, we focus on the latter two paradigms, which are thought to be related to the etiology 
and/or pathogenesis of psychiatric disorders. Cortese et al. (2016) selected confidence ratings as 
the target behavior during a two-choice dot-motion discrimination task in a cross-over DecNef 
study. (That is, the same participant performed two types of DecNef in a random order, separated 
by a 1-week interval: one aimed at increasing confidence ratings and one aimed at decreasing 
confidence ratings.) The authors reported that DecNef could be used to modulate activity in 
fronto-parietal regions to produce bi-directional alterations in confidence ratings without 
affecting task accuracy. Such a result would indicate that confidence is well decoded in higher 
cognitive areas, and that DecNef can be used to bi-directionally alter this meta-cognition-related 
behavior.  
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Koizumi et al. (2016) investigated whether the DecNef paradigm could be applied to 
fear extinction. In this experiment, pre-behavioral testing included fear-conditioning, in which 
fear responses were induced by pairing two kinds of colored circles (target fear-conditioned 
stimulus CS+ and control CS+) with electric shocks. Participants then underwent 3 days of 
DecNef training in which rewards were paired with the multi-voxel patterns of activity in V1/V2 
matched to the target CS+. After the training, fear responses as assessed by skin conductance 
response were selectively reduced for the target CS+ but not for control CS+. We emphasize that 
this counter-conditioning occurred even though participants were not explicitly exposed to any 
fear-related stimuli, but rather implicitly exposed to the neural activity patterns matched with the 
target CS+.  
The results of the latter two types of experiments—which may reflect alterations in 
meta-cognitive processes and the Pavlovian conditioned fear response—suggest that DecNef may 
be useful as an adjunctive therapy for psychiatric disorders, as meta-cognition and fear are closely 
related to behavioral changes associated with mental illness (David et al., 2012). In particular, 
counter-conditioning DecNef may benefit patients with fear-related disorders such as phobias and 
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post-traumatic stress disorder, as explicit exposure to traumatic situations (e.g., prolonged 
exposure therapy) may be too difficult for some patients (Schnurr et al., 2007).        
 
Functional-connectivity-based neurofeedback (FCNef) 
 The scope of fMRI-based neurofeedback now extends beyond controlling activation 
levels or patterns within ROIs to include regulation of functional connectivity between brain 
regions. Kim et al. (2015) demonstrated that the combination of ROI- and functional connectivity-
based neurofeedback for heavy smokers aided participants in inducing increased ROI activation 
and functional connectivity, which is accompanied by reduced cravings for nicotine. Another 
FCNef study used dynamic causal modeling to enhance the flow of information from the 
dorsomedial prefrontal cortex to the amygdala—the putative neural circuit associated with the 
cognitive control of emotions—successfully reducing state anxiety (Koush et al., 2015).    
These results indicate that specific regulation of FCs can indeed be achieved using FCNef, 
in turn leading to desired changes in behavior and function. Although such findings suggest that 
FCNef may represent a novel treatment method for psychiatric disorders, it remains unclear for 
how long FCNef-induced connectivity changes are retained. This issue was addressed by another 
recent study in which FC between the lateral parietal and primary motor areas, which were 
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negatively correlated prior to training, was enhanced via a 4-day FC-based neurofeedback training 
protocol (Megumi et al., 2015). This increase in functional connectivity during the training period 
resulted in positive alteration of the rs-fcMRI between the default-mode and motor/visuo-spatial 
networks, which include the two ROIs, respectively. Intriguingly, this effect lasted for more than 
2 months after the training. These results indicate that FCNef may be capable of inducing robust 
and long-lasting plasticity in target FCs, which is clinically significant for the treatment of 
psychiatric disorders. Yamashita et al. (2017) further demonstrated that FCNef induced 
bidirectional changes in behavior by changing the sign of a neurofeedback signal. Our hypothesis 
is as follows: If an rs-fcMRI-based biomarker capable of discriminating between individuals with 
a psychiatric condition and healthy controls with high accuracy can be developed, successful 
normalization of the individual’s own FC pattern using FCNef would lead to a reduction in 
psychiatric symptoms.   
 
Unique characteristics of DecNef and FCNef 
DecNef and the latter two FCNef (Megumi et al., 2015; Yamashita et al., 2017) studies 
have the following three unique characteristics; (i) implicitness, (ii) monetary reward, and (iii) 
spatially limited influence. First, no verbal instruction regarding any explicit strategy was given 
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to participants, and no participant became aware of how feedback was increased or the 
mechanisms underlying the neurofeedback experiment. Second, monetary reward was given to 
participants in proportion to the success of voxel pattern or functional connectivity induction. 
Third, induced information by DecNef and FCNef was largely constrained in the brain region. As 
for (i), no participant adopted a rational cognitive strategy that was fitted to the respective 
experimental designs, as revealed in post-experiment interviews (Shibata et al., 2011 and 2016; 
Megumi et al., 2015; Amano et al., 2016; Koizumi et al., 2016; Cortese et al., 2016 and 2017). 
When an efficient cognitive strategy is unavailable, desired brain activation can be reinforced by 
providing contingent feedback and/or rewards, rather than by the cognitive strategy itself. 
Therefore, reinforcement learning—or more specifically, neural operant conditioning—may well 
explain the training mechanism of DecNef and FCNef. However, in order to develop a clinically 
useful neurofeedback paradigm, it is necessary to compare the effect of various instruction, 
feedback, and reward conditions in future studies.  
 
Neurofeedback and pharmacology 
 When applying these fMRI-based neurofeedback methods to individuals with 
psychiatric disorders, it is necessary to consider the relationship between neurofeedback and 
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pharmacology, as many patients with such conditions are prescribed psychotropic agents. One 
previous study examined the interaction between neurofeedback and pharmacology in rodents 
(Ishikawa et al., 2014), reporting that mice were capable of inducing hippocampal neuronal 
activity through a neurofeedback operant conditioning method using lateral hypothalamus 
stimulation as a contingent reward. The authors further demonstrated that an NMDA receptor 
antagonist and dopamine D1 receptor antagonist abolished the neural operant conditioning. In 
contrast, depression model mice conditioned by forced swimming failed to induce target neural 
activity, although this ability was recovered following treatment with an antidepressant. These 
results suggest that psychotropic agents may act to either enhance or diminish the effect of 
neurofeedback in humans, indicating that combined treatment with neurofeedback and 
pharmacological agents may improve clinical outcomes.  
 
Neurofeedback therapy based on neuroimaging biomarkers 
 Based on the promising results of the aforementioned studies regarding rs-fcMRI-
based biomarkers and FCNef, several proof-of-concept studies have examined the potential 
efficacy of functional-connectivity-based neurofeedback in the treatment of patients with MDD 
and ASD (Hashimoto 2013; Kawato 2013; Yahata et al., 2016 and 2017). The most recent study 
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consists of (i) rs-fcMRI-based biomarker construction (see rs-fcMRI-based biomarker for 
psychiatric disorder) and (ii) normalization (i.e., FCs consisted of the biomarker) using an FCNef 
protocol. The protocol for normalization of target FCs was determined in large part based on a 
previous study (Megumi et al., 2015). Briefly, the FCNef training was held over 4 successive 
days. In each trial during the training, participants were instructed to manipulate brain activity to 
increase as much as possible the size of a green disc in the display, which represented the degree 
of target FC normalization. The following paragraphs discuss the preliminary findings of recent 
proof-of-concept experiments in individuals with MDD and ASD. These studies were approved 
by the ethical committee of Kyoto University and Showa University, respectively. All volunteers 
gave written informed consent prior to the study, in accordance with the Declaration of Helsinki.  
In the study of MDD, we selected FC between the left dorsolateral prefrontal cortex 
(DLPFC) and left precuneus/posterior cingulate cortex (Precun/PCC) as a target for FCNef, based 
on the following steps. First, we constructed two types of rs-fcMRI-based biomarker, one for 
predicting diagnosis (i.e., depression or healthy) (Ichikawa et al., 2017) and the other for 
predicting the severity of depressive symptoms (i.e., the score of BDI) (Yamashita et al., 2015). 
The target FC was defined as that included in both types of biomarkers. The identified FC was 
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consistent with the findings of previous studies that have demonstrated an imbalance in anti-
correlation between the default-mode and fronto-parietal networks as a neural correlate for MDD 
(Kaiser et al., 2015; Northoff, 2016; Rayner et al., 2016). During neurofeedback training, 
participants aimed to decrease the correlation of the target FC. In the most recent study, FCNef 
has been conducted for three individuals with MDD and seven individuals with subclinical 
depression. Participants with average BDI-II scores >10 at two different time points prior to 
training were categorized into the subclinical depression group. Figure 4a shows the 
neurofeedback scores of all three patients with MDD on each day of training. Scores exhibited an 
upward trend across the 4 days of training, and this was confirmed using a multiple regression 
model that included two explanatory variables (i.e., each training day and subject) and one 
response variable (i.e., neurofeedback scores), showing significant positive effect of the training 
day (95% confidence interval [CI] 1.9-9.1 of the coefficient). Post-hoc t-tests revealed that scores 
for all three participants were significantly higher on the last day than on the first (t = 4.01, p < 
0.001). These results consistently demonstrated that participants learned to induce negative 
correlation for the target FC throughout the training. Furthermore, all three patients exhibited 
decreased scores on the Hamilton Depression Rating Scale (HDRS) (Hamilton, 1980), which 
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represents the severity of depressive symptoms, after the training (Figure 4b). Similar to those of 
the depression group, neurofeedback scores also tended to increase over the training period among 
the seven individuals with subclinical depression (Figure 4c). One-way analysis of variance 
(ANOVA) revealed a significant main effect of training day (p = 0.011), while post-hoc paired t-
tests revealed that neurofeedback scores were significantly higher on the last day of training than 
on the first (p = 0.0046). A tendency for reduced BDI scores following training was also observed 
(p = 0.07). Furthermore, five of the seven participants also reduced the target rs-fcMRI in the 
normal direction, and the change in rs-fcMRI between pre- and post-FCNef was significantly 
correlated with that of BDI score (r = 0.87, p = 0.011) (Figure 4d). These results indicated the 
possibility that the target FC between the left DLPFC and left precuneus/PCC may be a 
theranostic biomarker for depression, as more than half of the participants decreased the target rs-
fc in accordance with BDI score through our FCNef training. Taken together, these findings 
suggest that our therapeutic package for depression can be used to detect potential theranostic 
biomarkers and ameliorate depressive symptoms using circuit-specific fMRI-based 
neurofeedback. 
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The integration of the FCNef technique with disease-specific rs-fcMRI-based 
biomarkers may also aid in the development of a novel therapeutic treatment for ASD. Using 
the highly accurate rs-fcMRI-based biomarker for ASD (Yahata et al., 2016), we conducted a 
proof-of-concept study of this approach in which a small number of adults with high-
functioning ASD underwent 4 to 5 successive days of FC-neurofeedback training (Hashimoto 
2013; Yahata et al., 2016 and 2017). In contrast to MDD, multiple FCs included in the ASD 
biomarker were selected as targets of intervention. Although the results are still preliminary and 
several aspects of the protocol must be refined, we observed steady improvement in feedback 
scores throughout the training in some participants. This observation indicates that some 
individuals with ASD are indeed capable of learning to change their altered FC patterns in the 
direction toward the typically-developed pattern, even in adulthood. Furthermore, we observed 
cases in which the neurofeedback training had a long-lasting impact on the FC pattern during 
the resting-state. The outputs of the rs-fcMRI-based biomarker closely approached the 
neurotypical level not only during the training sessions but also more than three weeks after the 
training, whereas, prior to training, the biomarker outputs had been invariably ASD-like. A 
typical case is shown in Figure 5. We acknowledge that even more robust changes in rs-fcMRI 
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may be required to induce behavioral changes that may significantly improve patient quality of 
life. Furthermore, several difficulties may exist that are specific to ASD, such as the altered 
sensitivity to reward (Dichter et al., 2012; Kohls et al., 2013). However, recent preliminary 
results suggest that real-time FCNef guided by the disease-specific rs-fcMRI-based biomarker 
may provide a foundation for the development of a novel neuro-circuitry-based therapy, 
particularly for conditions in which the effects of standard interventions are very limited, such 
as ASD. 
 
Figure 4 
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Figure 5 
 
 
Conclusion 
In this review, we discussed recent progress in computational psychiatric studies and 
the findings of our research program focusing on rs-fcMRI-based biomarkers and fMRI-based 
neurofeedback (DecNef project 2017). While not utilized in clinical psychiatry at present, these 
approaches have the potential to change the conventional method of symptom-based diagnosis to 
a data-driven method, allowing for more precise treatment with psychotropic agents and circuit-
specific therapies such as neurofeedback and rTMS. Furthermore, the combination of rs-fcMRI-
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based biomarkers and FCNef may allow for the simultaneous diagnosis and treatment of 
psychiatric disorders, thus establishing a theranostic biomarker, which has yet to be achieved in 
clinical psychiatry. 
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Figure 1: Distribution of weighted linear summations (WLS) calculated by functional 
connections. (a) The white and black bars denote the number of typically developing (TD) and 
autism spectrum disorder (ASD) individuals in the Japanese dataset, respectively. A horizontal 
axis denotes WLS score. If the WLS score is positive, an individual is classified as having ASD, 
while a negative WLS score indicates TD. (b) A histogram shows the distribution of WLS scores 
for the US ABIDE dataset. (c) The density distribution of WLS when applying the ASD classifier 
to various psychiatric conditions, such as (i) ASD, (ii) SCZ, (iii) ADHD, and (iv) MDD. In each 
panel, TD/healthy control distribution is gray-colored and ASD distribution is red-colored. The 
distribution of other psychiatric conditions (i.e., SCZ, ADHD, and MDD) is colored with blue, 
green, and yellow, respectively. AUC values are based on the classification between each 
psychiatric condition and TD/healthy control. P-values are obtained by the Benjamini-Hochberg-
corrected Kolmogorov-Smirnov test. The TD distribution of WLS at each panel is adjusted to 
have the same median and s.d. for the visualization purpose. Adapted, with permission, from 
Figure 1 and 5 in Yahata et al. A small number of abnormal connections predicts adult autism 
spectrum disorder. Nature Communications, DOI: 10.1038/ncomms11254 (2016). 
 
Figure 2: The procedure of decoded neurofeedback (DecNef). During training, participants were 
instructed to self-regulate brain activity so as to maximize the feedback score. This was 
represented by, for example, the size of a green disc, which corresponded to the participant’s 
success in inducing a current brain activity pattern as similar as possible to the target brain activity 
pattern.  
 
Figure 3: The procedure of functional connectivity-based neurofeedback (FCNef). During 
training, participants were instructed to self-regulate brain activity so as to maximize the feedback 
score. This was represented by, for example, the size of a green disc, which reflected the degree 
of  success in achieving target functional connectivity.  
 
Figure 4: Results from three individuals with depression and seven subclinical participants. (a) 
and (b) show the results of participants with depression. (c) and (d) show the results of participants 
with subclinical depression. (a) Neurofeedback scores across the four training days. Red bar 
denotes the mean of neurofeedback scores for all trials. Error bar denotes standard error of the 
mean. Asterisk shows the statistical significance (p < 0.001). (b) Hamilton Depression Rating 
Scale (HDRS) scores at pre- and post- functional connectivity-based neurofeedback (FCNef). Red 
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bar denotes the mean of HDRS scores and error bar shows standard error of the mean. (c) 
Neurofeedback scores in the same format as a. Asterisk shows the statistical significance (p < 
0.01). (d) Scatter plot of the change in the Beck Depression Inventory (BDI) score versus the 
change of the target rs-fcMRI between post- and pre- neurofeedback. Each dot represents 
individual data. The line denotes the linear regression of the change of BDI score from the change 
of the target rs-fcMRI.  
 
Figure 5: Neurofeedback-induced change of functional connectivity (FC) toward the 
neurotypical pattern in a case of adult high-functioning autism spectrum disorder (ASD). The 
graph shows the feedback scores during the training sessions (blank squares and error bars) and 
the outputs of the ASD biomarker (Yahata et al., 2016) using the resting-state FC data collected 
before (i.e., RS-1 and RS-2) and after (i.e., RS-3) the neurofeedback training (x signs). The 
open circle denotes the mean output of the ASD biomarker across the three rs-fcMRI sessions 
conducted in a single day. The output of the ASD biomarker ranged between 0 (typical ASD 
pattern) to 100 (neurotypical pattern). In each training day, there were six runs (filled squares 
and error bars; except for three runs in the final day), each of which had ten trials. Note that, 
whereas the outputs of the biomarker had remained close to 0 before the training, the resting 
state FCs exhibited the neurotypical pattern at least twice out of three scans in the post training, 
which was acquired three weeks after the training. 
 
 
 
 
 
